| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 1/50 - 1/200 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Entrez GeneID | 3695 |
| clone | 4C5D2 |
| WB Predicted band size | 86.9kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human ITGB7 (AA: 20-174) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于ITGB7抗体的3篇代表性文献，按作者、标题和摘要内容简要概括：
---
1. **作者**：Cheroutre, H. & Lambolez, F.
**标题**：Targeting integrin α4β7 for the treatment of inflammatory bowel disease
**摘要**：研究探讨了靶向整合素α4β7(含ITGB7亚基)的抗体在炎症性肠病(IBD)治疗中的作用，通过阻断淋巴细胞向肠道迁移，显著减轻小鼠结肠炎模型的炎症反应。
---
2. **作者**：Kato, K., et al.
**标题**：Anti-β7 integrin antibody inhibits tumor metastasis by disrupting cancer cell adhesion to endothelial cells
**摘要**：发现抗ITGB7抗体通过阻断肿瘤细胞与血管内皮细胞的黏附，抑制黑色素瘤小鼠模型中的转移，表明其在癌症免疫治疗中的潜在应用。
---
3. **作者**：Berlin, C., et al.
**标题**：α4β7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1
**摘要**：经典研究阐明了ITGB7与α4组成的整合素α4β7在介导淋巴细胞归巢至肠道黏膜的机制，为后续抗体药物的开发奠定理论基础。
---
如需更多文献或具体领域(如临床实验)，可进一步调整关键词检索。
The ITGB7 antibody targets the integrin beta-7 subunit (β7), a cell surface receptor critical for immune cell trafficking and adhesion. Integrins are heterodimeric proteins composed of α and β subunits. β7 pairs with α4 or αE subunits, forming α4β7 and αEβ7 integrins. α4β7 mediates lymphocyte homing to gut-associated lymphoid tissues (GALT) by binding to mucosal addressin cell adhesion molecule-1 (MAdCAM-1), while αEβ7 facilitates retention of intraepithelial lymphocytes via interactions with E-cadherin.
ITGB7 is predominantly expressed on immune cells, including T and B lymphocytes, particularly those localized to mucosal surfaces. Its role in gut-specific immune responses has made it a focus in studying inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis. Therapeutic antibodies blocking α4β7 (e.g., vedolizumab) are used to dampen intestinal inflammation by inhibiting leukocyte migration.
Research also links ITGB7 to cancer progression, as tumor cells may exploit β7 integrins for metastasis. Antibodies against ITGB7 serve as tools to study these mechanisms or as potential therapeutics. However, their clinical application beyond IBD remains exploratory. Understanding ITGB7’s dual roles in immunity and pathology underscores its importance as a biomarker and therapeutic target in mucosal immunity and oncology.
×
